BIOMAT Database Logo BIOMAT Database Logo

Synthesis and Structure-Activity relationship of 1-(5-isoquinolinesulfonyl)piperazine analogues as inhibitors of Mycobacterium tuberculosis IMPDH. 2019

Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
H3D Drug Discovery and Development Centre, Department of Drug Discovery and Development & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, 7701, Cape Town, South Africa; MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research & Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine & Department of Pathology, University of Cape Town, Anzio Road, Observatory, 7925, South Africa; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, 7701, Cape Town, South Africa. Electronic address: vinayak.singh@uct.ac.za.

Tuberculosis (TB) is a major infectious disease associated increasingly with drug resistance. Thus, new anti-tubercular agents with novel mechanisms of action are urgently required for the treatment of drug-resistant TB. In prior work, we identified compound 1 (cyclohexyl(4-(isoquinolin-5-ylsulfonyl)piperazin-1-yl)methanone) and showed that its anti-tubercular activity is attributable to inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH) in Mycobacterium tuberculosis. In the present study, we explored the structure-activity relationship around compound 1 by synthesizing and evaluating the inhibitory activity of analogues against M. tuberculosis IMPDH in biochemical and whole-cell assays. X-ray crystallography was performed to elucidate the mode of binding of selected analogues to IMPDH. We establish the importance of the cyclohexyl, piperazine and isoquinoline rings for activity, and report the identification of an analogue with IMPDH-selective activity against a mutant of M. tuberculosis that is highly resistant to compound 1. We also show that the nitrogen in urea analogues is required for anti-tubercular activity and identify benzylurea derivatives as promising inhibitors that warrant further investigation.

UI MeSH Term Description Entries
D007168 IMP Dehydrogenase An enzyme that catalyzes the dehydrogenation of inosine 5'-phosphate to xanthosine 5'-phosphate in the presence of NAD. EC 1.1.1.205. Inosinic Acid Dehydrogenase,Inosine-5-Monophosphate Dehydrogenase,Acid Dehydrogenase, Inosinic,Dehydrogenase, IMP,Dehydrogenase, Inosine-5-Monophosphate,Dehydrogenase, Inosinic Acid,Inosine 5 Monophosphate Dehydrogenase
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Synthesis and Structure-Activity Relationship of Xenocoumacin 1 and Analogues as Inhibitors of Ribosomal Protein Synthesis.
March 2021, ChemMedChem,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.
November 2004, Bioorganic & medicinal chemistry,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
November 2020, Bioorganic & medicinal chemistry letters,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors.
July 2018, Bioorganic & medicinal chemistry,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Synthesis and evaluation of thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
October 2002, Bioorganic & medicinal chemistry letters,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
April 2013, Bioorganic & medicinal chemistry,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Design and synthesis of purine connected piperazine derivatives as novel inhibitors of Mycobacterium tuberculosis.
November 2020, Bioorganic & medicinal chemistry letters,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions.
December 2002, Bioorganic & medicinal chemistry,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
April 2000, Bioorganic & medicinal chemistry letters,
Vinayak Singh, and Angela Pacitto, and Stefano Donini, and Davide M Ferraris, and Sándor Boros, and Eszter Illyés, and Bálint Szokol, and Menico Rizzi, and Tom L Blundell, and David B Ascher, and Janos Pato, and Valerie Mizrahi
Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors.
September 2011, European journal of medicinal chemistry,
Copied contents to your clipboard!